Morgan Stanley Maintains Equal-Weight on Evofem Biosciences, Lowers Price Target to $1
Morgan Stanley analyst Jeffrey Hung maintains Evofem Biosciences (NASDAQ:EVFM) with a Equal-Weight and lowers the price target from $3 to $1.
Evofem Biosciences: Q2 Earnings Insights
Shares of Evofem Biosciences (NASDAQ:EVFM) decreased 2.7% in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share increased 30.77% over the past year to ($0.27), which beat the estimate of ($0.41).
The Daily Biotech Pulse: FDA Rejects FibroGen’s Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 10)
Earnings Scheduled For August 11, 2021
Companies Reporting Before The Bell
• Wireless Telecom Group (AMEX:WTT) is likely to report earnings for its second quarter.
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.
28 Stocks Moving in Wednesday’s Pre-Market Session
Gainers
Chembio Diagnostics, Inc. (NASDAQ: CEMI) shares rose 78.2% to $3.67 in pre-market trading after dropping more than 16% on Tuesday. Chembio’s filing recently showed registration for $60 million common stock offering.
58 Biggest Movers From Yesterday
Gainers
BM Technologies, Inc. (NYSE: BMTX) shares climbed 26.4% to close at $11.82 on Tuesday after the company reported record Q1 results.